DVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DaVita Inc (DVA) does not present a compelling buy opportunity at this time for a beginner investor with a long-term focus. Despite positive price momentum and some bullish indicators, the lack of strong proprietary trading signals, insider and hedge fund selling, and mixed financial performance suggest holding off for now.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), indicating a positive trend. However, the MACD histogram is negative (-0.48) and contracting, suggesting weakening momentum. RSI is neutral at 74.518, and the stock is trading near its resistance level (R1: 155.799, R2: 158.416).
Analyst upgrades with increased price targets (e.g., UBS raised to $190 citing strong EPS growth and accretive acquisitions). The company’s Q4 financials showed a 9.87% YoY revenue increase and improved gross margin (+4.09%).
Hedge funds and insiders are heavily selling the stock, with hedge fund selling up 6939.07% and insider selling up 267.89%. Net income dropped by -9.68% YoY in Q4 2025, and the stock shows a 30% chance of declining -8% in the next month based on candlestick patterns.
In Q4 2025, revenue increased by 9.87% YoY to $3.62 billion, and EPS rose by 6.47% YoY to 3.29. However, net income dropped by -9.68% YoY to $234.2 million, indicating profitability challenges despite revenue growth. Gross margin improved to 28.28% (+4.09% YoY).
Analysts have mixed ratings. UBS maintains a Buy with a price target of $190, citing strong EPS growth and acquisitions. Truist, TD Cowen, and Barclays maintain Hold or Equal Weight ratings with price targets between $144 and $158. Analysts highlight positive guidance but note challenges like mixed volume trends and prior-year losses.
